Jump Financial LLC Makes New $60,000 Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Jump Financial LLC purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQSTFree Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 29,812 shares of the company’s stock, valued at approximately $60,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Armistice Capital LLC lifted its position in Aquestive Therapeutics by 314.5% during the third quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after acquiring an additional 3,642,000 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Aquestive Therapeutics by 238.8% during the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock valued at $841,000 after purchasing an additional 388,017 shares during the last quarter. Legato Capital Management LLC acquired a new stake in shares of Aquestive Therapeutics in the 4th quarter worth $688,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Aquestive Therapeutics by 14.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after purchasing an additional 30,898 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Down 5.2 %

NASDAQ:AQST opened at $2.91 on Friday. The stock has a 50 day moving average of $3.69 and a two-hundred day moving average of $3.08. Aquestive Therapeutics, Inc. has a 12 month low of $1.25 and a 12 month high of $6.23. The firm has a market cap of $264.93 million, a P/E ratio of -6.93 and a beta of 2.95.

Aquestive Therapeutics (NASDAQ:AQSTGet Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The company had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $12.22 million. During the same period in the prior year, the company posted $0.11 earnings per share. On average, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on AQST shares. SVB Leerink started coverage on Aquestive Therapeutics in a report on Friday, May 10th. They issued an “outperform” rating and a $8.00 price target for the company. Piper Sandler assumed coverage on shares of Aquestive Therapeutics in a research report on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price on the stock. JMP Securities raised their price target on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Friday, March 15th. Raymond James assumed coverage on shares of Aquestive Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $7.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, May 9th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $8.00.

View Our Latest Analysis on Aquestive Therapeutics

Insider Transactions at Aquestive Therapeutics

In related news, insider Alexander Mark Schobel sold 50,000 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $6.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider now owns 984,476 shares of the company’s stock, valued at approximately $5,906,856. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 7.85% of the company’s stock.

Aquestive Therapeutics Company Profile

(Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Recommended Stories

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQSTFree Report).

Institutional Ownership by Quarter for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.